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Bone marrow (BM) cells contribute to the maintenance and
repair of several compartments of the kidney, including the
endothelium, interstitium, epithelium, and the mesangium.
The aim of this study was to explore the therapeutic use of
bone marrow-derived cells (BMDC) that can differentiate into
endothelial and mesangial cells in a model of progressive
glomerulosclerosis. To investigate the involvement of BMDC
in glomerular repair, progressive glomerulosclerosis was
induced in enhanced green fluorescent protein BM chimeric
rats by a one-shot injection of anti-Thy-1.1 monoclonal
antibody, followed by unilateral nephrectomy. Subsequently,
these rats were treated with either a BM cell infusion or
phosphate-buffered saline. Renal function, intravital
glomerular hemodynamics, and histological alterations were
examined 12 weeks after anti-Thy-1.1 monoclonal antibody
injection. Inflammatory infiltration of macrophages in the
kidneys was evaluated by immunofluorescence of ED-1. We
also determined whether BMDC contributed to repair and
regeneration of endothelial and mesangial cells by
immunofluorescence monitoring. As a result, BM cell infusion
improved renal function and glomerular hemodynamics, and
histological alterations with reduced glomerular infiltration
of macrophages, leading to dramatically reduced mortality
in this model of progressive glomerulosclerosis. We also
demonstrated that, in the BM cell infusion group, more
BMDC contributed to repair and regeneration of endothelial
and mesangial cells than in the untreated group. The
present study provides us with a conceptual basis for the
development of therapeutic stem cell strategies aimed at
enhancing recovery from progressive glomerulosclerosis.
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In the normal glomerulus, the endocapillary region is a
closed space surrounded by the glomerular basement
membrane and is functionally separated by the hydrostatic
pressure across the glomerular capillary wall. For the
maintenance of normal glomerular function, construction
of the physiological structure composed of endothelial cells,
mesangial cells, and mesangial matrices in a well-balanced
way is necessary.1 Once glomerular damage occurs, glomer-
ular function may be disturbed before effective repair of
glomerular cell and matrix components occurs. There is
accumulating evidence that persistent disturbances of the
regenerative process of glomerular capillary tufts may lead to
irreversible progressive glomerulosclerosis.2–6
There is increasing evidence that bone marrow (BM) cells
can differentiate into a wide range of specialized cells, such as
hepatocytes,7,8 cardiomyocytes,9 and skeletal muscle cells.10
BM cells contribute to the maintenance and repair of several
compartments of the kidney, including the endothelium,11
interstitium,12 epithelium,13 and the mesangium.14,15 This
plasticity of stem cells may be useful in therapeutic strategies
designed to enhance tissue regeneration after severe organ
injury. Bone marrow transplantation has been used as a tool to
investigate the various roles of BM cells in glomerular diseases.
Very recently, our work using the enhanced green
fluorescent protein (EGFP) transgenic rat16 supported the
idea, proposed by Rookmaaker et al.,11 that BM-derived
endothelial precursor cells were involved in the recruitment
of glomerular endothelial cells in anti-Thy-1 antibody (Ab)-
induced glomerular injury. This line of approach enabled us
to undertake trials of treatment for regeneration using bone
marrow transplantation, as highlighted in stem cell admin-
istration therapy of other organs. To explore therapeutic
strategies of BM cell infusion, we selected the experimental
model of progressive glomerulosclerosis, which can be
induced in the rat by a single injection of anti-Thy-1.1
monoclonal Ab, followed by unilateral nephrectomy.2 In
particular, irreversible glomerular sclerosis in BM chimeric
rats, transplanted with EGFP (þ ) BM cells, is much more
severe.16 If no treatment was given, most rats died by 12
weeks after injection of anti-Thy-1.1 Ab.
Here, we focus on the therapeutic effect of BM cell infu-
sion on the prognosis of fatal, progressive glomerulosclerosis
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in terms of histopathological and glomerular hemodynamics
analysis.
RESULTS
Infusion of BM cells markedly decreased mortality in the
progressive glomerulosclerosis rat model
As reported in our recent study,16 this experimental rat
model was chosen, as it is easier to induce progressive
glomerulosclerosis and death from chronic renal failure than
in other rat systems. In our present study, only two of eight
untreated rats survived. The other six rats died at 2, 3, 5, 7
and 8 weeks after 1-22-3 Ab injection. However, five of six
BM cell-infused rats survived till 12 weeks, only one died at 9
weeks (Figure 1), suggesting that bone marrow-derived cells
(BMDC) were a useful therapeutic strategy after progressive
glomerulosclerosis.
Chimeric rats display no evidence of radiation-induced renal
dysfunction
Five weeks after irradiation, we determined renal function
and other general characteristics in chimeric rats. As shown
in Table 1, serum creatinine (0.2770.15 mg/dl), blood urea
nitrogen (17.973.7 mg/dl) and 24-h protein excretion
(2.3774.65 mg/24 h) in chimeric rats 5 weeks after irradia-
tion were similar to those observed in control rats
(0.3070.21, 18.475.5 mg/dl and 2.1571.94 mg/24 h, respec-
tively). In addition, we also found no significant differences
in serum total protein, albumin and total cholesterol between
control and chimeric rats (Table 1).
BM cell infusion ameliorated renal dysfunction
We also examined whether BMDC have an impact on renal
function. Following Ab injection and Nx, all rats had renal
dysfunction with significant increases in serum creatinine
from levels of 0.2770.15 to 2.5971.87 mg/dl in the
untreated group and 1.5670.87 mg/dl in the BM cell
infusion group. All rats had a significant increase in the
serum blood urea nitrogen from levels of 18.073.7
to 217.1.37185.5 mg/dl in the untreated group and
121.1781.2 mg/dl in the BM cell infusion group. However,
renal function in animals with BM cell infusion was
significantly better than in untreated animals throughout
the study (Table 1).
Urinary protein excretion was determined on days 3, 7, 14,
28, 42, 56, 70, and 84 after anti-Thy-1.1 monoclonal Ab
injection. Up to 42 days after Thy-1 Ab injection, urinary
protein excretion in both BM cell infusion-treated and
-untreated groups were apparently higher than that in
controls, but no significant differences between the two
groups was seen. In the untreated group, urinary protein
excretion sharply increased with time, up to 229.37
102.8 mg/24 h. In the BM cell infusion group, urinary protein
excretion also increased with time. However, it was signifi-
cantly lower than in the untreated group from days 56 to 84
after injection of Thy-1 Ab (Figure 2), suggesting that BMDC
could partly repair renal injury and lower urinary protein
excretion.
Light microscopy
Glomerular alterations were examined on week 12 after anti-
Thy-1 Ab injection by light microscopy. Sequential renal
histology during course the of disease, as described recently
in the same experimental schedule,16 was abbreviated here.
On day 84, in the untreated group, severe mesangial cell
proliferation with matrix expansion was observed in the
majority of the glomeruli. Many glomeruli showed crescentic
lesions and diffuse tubular atrophic changes with interstitial
cell infiltration (Figure 3a and b). Only moderate mesangial
cell proliferation with mesangial matrix and mild crescentic
lesions were observed in the BM cell infusion group (Figure
3c and d). No pathological findings were observed in the
chimera group (Figure 3e). The mesangial expansion index
and glomerular sclerosis index in the untreated group were
Table 1 | Serum biochemical analysis and urinary protein excretion
N TP (g/dl) Alb (g/dl) TC (mg/dl) BUN (mg/dl) Cr (mg/dl) UP (mg/day)
Control 14 6.370.5 4.270.3 99.8726.4 18.475.5 0.3070.21 2.1571.94
BM-chimera 14 6.770.3 4.470.2 103.6715.7 18.073.7 0.2770.15 2.3774.65
Untreated 4 5.570.9a 3.170.6a 192.8734.1b 217.17185.5b 2.6071.87b 229.37102.8b
BM cell infusion 5 5.870.9a 3.570.7a 174.8727.5b 121.1781.2b,c 1.5670.87b,c 138.8745.2b,c
TP=total protein; Alb=albumin; TC=total cholesterol; BUN=blood urea nitrogen; Cr=creatinine; UP=urinary protein excretion.
Each value is expressed as mean7s.d. Data in BM-chimeric rats were obtained at 5 weeks after irradiation. Data in untreated group and BM cell infusion group were obtained
at 7 and 12 weeks, respectively, after Thy 1 antibody injection.
aPo0.05 vs control Po0.01.
bPo0.01 vs control rats.
cPo0.01 BM cell infusion group vs untreated group.
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Figure 1 | Survival rate. K, Untreated group (n¼ 8); J, BM cell
infusion group (n¼ 6).
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significantly higher than the BM cell infusion group (Figure
3f and g). Light microscopic findings in the present study also
showed that progressive glomerulosclerotic lesions, asso-
ciated with renal insufficiency, occurred in the untreated
model, as described previously.2
Effect of BM cell infusion on glomerular infiltration of
macrophages
Macrophages seem to play a crucial pathogenic role in most
experimental nephropathies and human glomerular diseases.
Macrophages are also reported to be involved in stimulating
mesangial cell proliferation and inducing glomerulosclero-
sis17,18 because they secrete a number of mitogenic and/or
fibrogenic cytokines, and growth factors.19 Therefore, we
examined the effect of BM cell infusion on glomerular
infiltration of macrophages by immunofluorescence. As
shown in Figure 4, many ED-1-positive macrophages are
found in the glomeruli in untreated rats (Figure 4a). In
contrast, the glomerular ED-1-positive macrophages are
significantly reduced after BM cell infusion administration,
and a few of these cells are seen in the glomeruli in the BM
cell infusion group (Figure 4b and c).
Real-time observation of glomerular micro
circulation by CSU-10
A new mapping system developed by our lab allowed us to
observe glomerular microcirculation in vivo. Figure 5 also
shows the typical images of glomerular tufts in untreated
(Figure 5a and b) and BM cell infusion (Figure 5c and d)
groups. In the untreated group, some glomeruli showed a
single avascular mass that appeared to correspond to the
glomerulosclerotic lesion, compressing capillary tuft. As
shown in Figure 5a and b, in only a small part of this
glomerulus, movements of red blood cells were observed and
the glomerular microcirculation was almost stopped. We
followed a series of movements of red blood cells within the
glomerular microvasculature and in the extraglomerular
vessels. As shown in Figure 5a and b, red blood cellss within
the glomerular microvasculature moved extremely slowly.
Treatment with BM cell infusion significantly ameliorated
this alteration. As shown in Figure 5c and d, movements of
red blood cells with a near-normal speed was seen in the
whole glomerulus. Erythrocyte velocities within the glomer-
uli were markedly faster in the BM cell infusion group,
compared with the untreated rats (Figure 5e). Treatment with
BM cell infusion caused a significant increase in the number
of glomerular BMDC that may contribute to glomerular
endothelial and mesangial cell repair.
Confocal laser scanning immunofluorescent microscopy,
in combination with immunostaining and optical sectioning
of isolated glomeruli, allowed three-dimensional analysis and
characterization of EGFP (þ ) BMDCs within the glomeruli.
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Figure 2 | Urinary protein excretion. Urinary protein excretion was
determined in 24 h urine specimens at the times indicated after
injection of 1-22-3 Ab. Data are expressed as mean values7s.d.
Po0.05 vs untreated group. &, Untreated group; ’, BM cell infusion
group.
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Figure 3 | Light microscopic findings. (a and b) In the untreated
group, severe mesangial cell proliferation with matrix expansion was
observed in the majority of the glomeruli. Many glomeruli showed
crescentic lesions and diffuse tubular atrophic changes with
interstitial cell infiltration. (c and d) Only moderate mesangial cell
proliferation with increase in mesangial matrix and mild crescentic
lesions were observed in the BM cell infusion group. (e) No
pathological findings were observed in the chimera group. (f) The
mesangial expansion index and (g) glomerular sclerosis index in the
untreated group were significantly higher than the BM cell infusion
group (periodic acid-Schiff stain). The data indicated in (f) and (g) are
means7s.d. *Po0.05 vs untreated group; **Po0.01 vs untreated
group (bars¼ 50mm).
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In the present work, we have focused on the role of BMDCs
in the regeneration of resident glomerular cells after severe
glomerular damage. In the chimeric control rats without the
administration of 1-22-3 Ab, only a few cells were observed
within glomeruli (Figure 6a). Twelve weeks after the
administration of 1-22-3 Ab in chimeric rats, we found that
treatment with BM cell infusion (Figure 6c) caused a
significant increase in the number of glomerular BMDC
compared with the untreated group (Figure 6b). The same
result could be expressed graphically, as shown in Figure 6d.
We also examined the recruitment of BMDC into the
glomeruli in the two groups by immunofluorescence with
cell-specific markers. Figures 7, 8, and 9 shows intraglomer-
ular cells expressing EGFP and either rat endothelial cell
antigen (RECA)-1 or platelet–endothelial cell adhesion
molecule-1 (PECAM-1) as an endothelial cell marker, or
OX-7 as a mesangial cell marker. Colocalization of EGFP and
RECA-1, PECAM-1 or OX-7 generated a yellow fluorescence.
In the untreated group, relatively few EGFP (þ ) cells
colocalized with RECA-1 (Figure 7e), PECAM-1 (Figure 8e)
or OX-7 (Figure 9e). In contrast, there were many EGFP (þ )
cells that were costained with RECA-1 (Figure 7f), PECAM-1
(Figure 8f) or OX-7 (Figure 9f) in the BM cell infusion
group. The same results could be expressed graphically, as
shown in Figures 7g, 8g, and 9g.
The maintenance of the microvasculature would appear to
be critical for the prevention of progressive renal disease.20 To
analyze glomerular capillary regeneration, we used RECA-1
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Figure 4 | Inhibitory effect of glomerular infiltration of
macrophages by BM cell infusion administration. Representative
photomicrographs of immunofluorescent staining for glomerular
ED-1 of (a) untreated rats and (b) BM cell infusion rats. The mean
number of glomerular ED-1-positive cells per glomerulus was shown
in graph (c). The data indicated in (c) are means7s.d. **Po0.01 vs
untreated group (scale bars¼ 50mm).
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Figure 5 | (a and b) Representative images showing movement of
red blood cells in glomerular microvasculature show a typical
feature of a glomerulus from an untreated rat on day 84. A small
ball-like lesion was seen without blood flow. (c and d) A typical
feature of a glomerulus from a BM cell-infused rat on day 84. Blood
flow could be observed in the whole glomerulus. Arrowheads in
(a) and (c) show the starting point. Arrowheads in (b) and (d) show
the end point (bars¼ 10mm). (e) The mean erythrocyte velocities
within the glomeruli in two groups. All data were expressed as mean
means7s.d. **Po0.01 vs untreated group.
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Figure 6 | Recruitment of EGFP (þ ) BM cells into the glomeruli on
day 84 after the injection of 1-22-3 Ab. (a) Chimeric control rat,
(b) untreated rat, (c) BM cell-infused rat and (d) graphs showed mean
number of BMDC in glomeruli of three groups (N¼ 30 each group).
**Po0.01 vs chimeric control group. ##Po0.01 vs untreated group
(scale bars¼ 50mm).
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as markers for endothelial cells to evaluate the number of
glomerular capillaries. As shown in Figure 10, evident loss of
glomerular endothelium occurred in the untreated group
(Figure 10a). However, treatment with BM cell infusion
(Figure 10b) significantly increased the number of endo-
thelial cells in glomerular capillaries. The same result could
be expressed graphically, as shown in Figure 10c. Further-
more, more BMDC were found to be involved in the repair
and regeneration of endothelial cells of glomerular capillaries,
ameliorating progressive glomerulosclerosis in this experi-
mental rat model (Figure 7f).
DISCUSSION
During the repair of glomerular structures after injury, the
revascularization process is a critical factor-determining
prognosis of glomerular injury. From a therapeutic view-
point, delivery of BM-derived endothelial precursor cells or
passive administration of BM-derived endothelial precursor
cells, and coincidental activation of angiogenesis and/or
vasculogenesis by transfer of factors such as vascular
endothelial growth factor, hepatocyte growth factor, and
the relevant genes should be investigated as a means of
promoting recovery and preventing irreversible progression
to glomerulosclerosis.
Very recently, we achieved induction of progressive
glomerulosclerosis with renal insufficiency in BM chimeric
rats, transplanted with EGFP (þ ) BM cells from litter-
mates,16 based on our original model of irreversible
progressive glomerulosclerosis, induced by a one-shot injec-
tion with 1-22-3 Thy-1 Ab combined with nephrectomy.2 In
this one-kidney model, most chimeric rats died of uremia
8–11 weeks after disease induction.
The present study showed that BM cell infusion
ameliorates progressive glomerulosclerosis in an experimen-
tal rat model, as exemplified by dramatically reduced mor-
tality and improvement of both pathohistological findings
and renal function, including glomerular hemodynamics.
In the BM cell infusion group, a much higher number of
BMDC contributed to the recruitment and regeneration of
glomerular endothelial and mesangial cells than seen in the
untreated group.
Glomerular endothelial injury plays an important role in
the pathogenesis of renal diseases and is centrally involved in
renal disease progression. Glomerular endothelial repair may
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Figure 7 | Immunofluorescent double staining for endothelial
cells (RECA-1) with glomerular sections from either (b, d, f) BM
cell infusion or (a, c, e) untreated rat on day 84 after injection of
1-22-3 Ab. (a and b) Staining for EGFP (þ ) cells (green). (c and d)
Staining for endothelial cells (RECA-1, red). (e and f) Double staining
identifies BM-derived endothelial cells marked with arrows (yellow)
(scale bars¼ 50 mm). (g) The mean number of BM-derived endothelial
cells per glomerulus was shown in the graph. The data indicated in
(g) are means7s.d. **Po0.01 vs untreated group.
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Figure 8 | Immunofluorescent double staining for endothelial
cells (PECAM-1) with glomerular sections from either (b, d, f) BM
cell infusion or (a, c, e) untreated rat on day 84 after injection of
1-22-3 Ab. (a and b) Staining for EGFP (þ ) cells (green). (c and d)
Staining for endothelial cells (PECAM-1, red). (e and f) Double staining
identifies BM-derived endothelial cells marked with arrows (yellow)
(scale bars¼ 50mm). The mean number of BM-derived endothelial
cells per glomerulus was shown in graph (g). The data indicated in (g)
are means7s.d. **Po0.01 vs untreated group.
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help maintain renal function. There is accumulating evidence
that impaired regeneration of glomerular capillaries may
result in irreversible renal sclerosis.2,5,20 Glomerular mesan-
gial cells provide structural support in the glomerular
capillary tufts. Injured mesangial cells owing to pathologic
conditions such as glomerulonephritis and diabetic nephro-
pathy leads to impaired renal function as well. Therefore,
repair process following glomerular injury needs well-
balanced recruitment of glomerular endothelial and mesan-
gial cells. In present study, immunofluorescent staining with
specific cell markers revealed that increased number of
BMDC in BM cell infusion group contributed to glomerular
endothelial and mesangial repair and regeneration, compared
with untreated group. The maintenance of glomerular
capillary number would help maintain glomerular hemo-
dynamic function including glomerular filtration rate.
It is now established that BM-derived endothelial
precursor cells can differentiate into endothelial cells that
participate in angiogenesis or vasculogenesis in postnatal
neovascularization.21–24 The present work reconfirmed that,
in anti-Thy-1 Ab-mediated glomerulonephritis models,
BMDCs could be recruited and integrated into glomerular
structures, as described by Ito et al.,14 Rookmaaker et al.,11
Uchimura et al.,25 and ours.16 In chimeric rats, transplanted
with BMDCs, recruitment of BMDC was rarely found. In
contrast, BMDC were mobilized to replace glomerular
endothelial and mesangial cells after damage. This result
indicated that BM stem cell plasticity might not just be a
physiological function, but that they may also be incorpo-
rated into the lesions of severe injury under active selection.
This could occur via gradient concentrations of chemo-
attractant growth factors, such as platelet-derived growth
factor, vascular endothelial growth factor, and hepatocyte
growth factor. It is reasonable to think that resident BMDCs
and/or transfused BM cells for therapeutic use can be
incorporated into glomerular cellular compartments after
severe damage, resulting in the repair of glomerular
structures and improvement of function. This study showed
that bone marrow cell infusion contributes to the increase in
the number of EGFP (þ ) cells within the diseased glomeruli,
but could not discriminate whether these EGFP (þ ) cells
may be originated from the resident bone marrow cells and/
or injected EGFP (þ ) BM cells for the treatment. Future
studies using maker combination such as Y-chromosome or
b-galactosidase will clarify the origin of EGFP (þ ) cells.
From the results of this study, we cannot exclude the
possibility that cell fusion of BMDCs with the remaining
intrinsic glomerular cell components occurred. BM cells have
the capacity to fuse not only with embryonic stem cells and
differentiate in vitro26 but also with host hepatocytes,
resulting in the regeneration in a mouse model of
tryosinemia.27 In contrast, Harris et al.28 provided evidence
that pulmonary, hepatic, and dermal epithelial cells devel-
oped from BMDCs without cell fusion, using the refined
method of the Cre/lox recombinase system. In general,
frequency of cell fusion in culture system is considered to be
very low, at the level of once in 104–105 cells.29 In addition,
even when cell fusion occurred in adult cells between two
different lines, the specific cellular function may be disturbed
in such a heterokaryonic, genetically abnormal cell. Very
recently using the same one-kidney model of progressive
glomerulosclerosis, we reported that BM-derived EGFP (þ )
cells expressed the endothelial cell-specific marker, PECAM-1,
known to be a cell adhesion marker, as well as RECA-1, in
addition to their production of von Willebrand factor.16 In
our preliminary study, microvascular function of intertubular
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Figure 9 | Immunofluorescent double staining for mesangial cells
(OX-7) with glomerular sections from either (b, d, f) BM cell
infusion or (a, c, e) untreated rat on day 84 after injection of
1-22-3 Ab. (a and b) Staining for EGFP (þ ) cells (green). (c and d)
Staining for mesangial cells (OX-7, red). (e and f) Double staining
identifies BM-derived mesangial cells marked with arrows (yellow)
(scale bars¼ 50 mm).
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Figure 10 | Vessel number in the glomeruli on day 84 after the
injection of 1-22-3 Ab. (a) Untreated rat, (b) BM cell-infused rat and
(c) graphs showed mean vessel number in the glomeruli of two
groups (N¼ 20 each group). **Po0.01 vs untreated group (scale
bars¼ 50 mm).
328 Kidney International (2006) 69, 323–330
o r i g i n a l a r t i c l e B Li et al.: BM cell infusion ameliorates progressive glomerulosclerosis
endothelial cells reconstituted with BMDCs, as represented
by blood flow analysis, was restored to normal levels after
ischemia–reperfusion injury in the same system using EGFP
transgenic rats (manuscript in preparation). From the
viewpoint of function, it is reasonable to consider that BM-
derived endothelial progenitor cells can recruit and repair the
damaged glomerular capillary tuft without cell fusion.
Further studies on cell fusion and also on cytokines inducing
cell homing and neoangiogenesis of BM-derived progenitor
cells in the microenvironment of glomeruli will be needed.
Our findings provide us a conceptual basis for the
development of therapeutic strategies aimed at stem cells in
an effort to enhance recovery from progressive glomerulo-
sclerotic diseases.
MATERIALS AND METHODS
Animals
Transgenic Sprague–Dawley rats carrying the EGFP transgene rat were
purchased from Japan SLC Inc. (Hamamatsu, Tokyo, Japan; with
permission from Dr M Okabe, Osaka University, Osaka, Japan) and
were maintained and crossmated to obtain littermates of EGFP (þ )
and EGFP () (wild-type) rats. The animals were kept in filter top
cages and received sterilized food and acidified water ad libitum. EGFP
rats were originally established by use of the same construct and
technique described for the production of EGFP transgenic mice.30
The expression of EGFP was under the control of the cytomegalovirus
enhancer and the chicken beta-actin promoter, derived from an
expression vector, pCAGGS. All experimental protocols were approved
by the animal committee of Niigata University, Niigata, Japan.
Chimeric rats and bone marrow transplantation
When rats were 5 weeks old, bone marrow transplantation was
performed using Sprague–Dawley rats (wild-type, EGFP ()) as
recipients, and their siblings EGFP (þ ) as donors. EGFP (þ ) rat
BM was collected by flushing bone shafts of femurs, tibiae, and
humeri of EGFP rats with phosphate-buffered saline. After sieving
through 75 and 50 mm meshes, the cells were resuspended at a
concentration of 1–2 108 cells/ml and kept on ice until use.
Littermate rats of wild-type, EGFP () were lethally irradiated
(10 Gy per animal with an X-ray generator (PS-3000 SB Cs-137;
Pony Industry Co. Ltd, Osaka, Japan)), and within 4 h after
irradiation, BM cells were administered via the tail vein.
Experimental protocol
Five weeks after bone marrow transplantation, experimental
progressive glomerulosclerosis was induced in 14 chimeric rats by
a single intravenous injection of the monoclonal anti-rat Thy-1.1 Ab
(1-22-3, mouse IgG3, 1 mg/kg/body weight),31 and then 30 min after
injection, unilateral nephrectomy of the left kidney was performed,
according to the protocol described previously.2 These chimeric rats
were divided into two groups. In the treatment group, on day 7 after
the injection of 1-22-3 Ab, 1 108 BM cells from sibling EGFP (þ )
donors were infused intravenously (BM cell infusion group, n¼ 6).
As a control group, chimeric rats with unilateral nephrectomy after
anti-Thy-1.1 Ab injection (untreated group, n¼ 8) were not given
any treatment, leading to death owing to renal insuffiency by 84 days
glomerular hemodynamics in rats, including two survivors without
treatment with BM cell infusion were examined by CSU-10 and
killed on day 84 after the administration of 1-22-3 Ab.
Biochemical analysis of serum
Serum total protein as well as concentrations of albumin, total
cholesterol, creatinine, and blood urea nitrogen were measured.
Urinary analysis
Chimeric rats, with anti-Thy-1 nephritis, were individually housed
in metabolic cages with free access to water, for collection of 24-h
urine specimens, on day 3, and at weeks 1, 2, 4, 8, and 12 after
injection of 1-22-3 Ab. The amount of urinary protein excreted was
determined by the biuret method using bovine serum albumin as a
standard.32
Light microscopy
Tissue for light microscopy was fixed in 10% neutral-buffered
formalin. The fixed material was embedded in paraffin, cut at a
thickness of 4 mm and sections were stained with periodic acid-
Schiff. Mesangial expansion and glomerular sclerosis were
graded semiquantitatively on a scale of 0 to 4þ , as reported
previously.33
Intravital observation of the renal microcirculation
Observation of microcirculation blood flow was made with an
intravital microscope system (Nikon, Tokyo, Japan), equipped with
a real-time confocal scanner unit model CSU-10 and image
processing devices, as described previously.32 The rats were
anesthetized by intraperitoneal injection of thiobutabarbital sodium
salt (100 mg/kg). Polyethylene catheters (PE50) were inserted into
the carotid artery for blood pressure measurements and into the
femoral vein for administrating labeled plasma components and
autologous red blood cells. The left kidney was exposed by a flank
incision and split longitudinally. The surface of the kidney was cut
1 mm deep with a razor blade, and the kidney was placed under the
confocal laser scanning immunofluorescent microscopy to analyze
the glomerular microcirculation at the surface. Fluorescein iso-
thiocyanate-labeled dextran (FITCDx, MW 150 000; Sigma, St.
Louis, MO, USA) was injected to visualize the microvascular archi-
tecture, and fluorescein isothiocyanate-labeled autologous red blood
cells were injected to observe the erythrocyte velocity as described
previously.32
Examination of cell markers on frozen sections
by immunofluorescence
Indirect immunofluorescence was performed on 3 mm frozen
sections fixed with cold acetone as described previously.16 Sections
were stained with the primary Ab at 41C overnight, and washed with
phosphate-buffered saline. Incubation with the second Ab was for
1 h at room temperature. The primary antibodies were OX-7, anti-
rat Thy-1 mouse Ab34 (a hybridoma producing OX-7 IgG1 was
purchased from European Collection of Animal Cells Porton Down,
Salisbury, UK) for identifying glomerular MC; anti-rat PECAM-1
and anti-rat RECA-1 mouse Abs (Serotec Ltd, Kindlington, UK) for
identifying glomerular endothelial cells; and anti-rat ED-1 mouse
Abs (Serotec Ltd., Kindlington, UK) for detecting infiltrating
macrophages. The secondary Ab was tetramethyl rhodamine B
isothiocyanate-conjugated anti-mouse Ig Ab (Dako, Glostrup,
Denmark). For conventional immunofluorescence of the sections,
we used a confocal laser scanning immunofluorescent microscopy,
with the MRC-1024 confocal imaging system (Bio-Rad Laboratories,
Hemel Hempstead, UK).35 The mean value of vessel number, GFP-
positive cells, ED-1-positive cells, BM-derived endothelial cells, and
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mesangial cells were counted in a blinded manner by two unrelated
researcher in at least 30 glomeruli per kidney.
Statistical analysis
All values are given as mean7s.d. One-way analysis of variance with
Steel–Dwass test was employed to analyze multiple comparison.
Kaplan–Meier analysis was used to analyze the survival rate.
Comparisons between two groups were carried by unpaired t-test.
P-values less than 0.05 were considered significant in all statistical tests.
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